Coronavirus patent set to fail; Qualcomm’s licensing surge; Ex-Ericsson CIPO calls for differential 5G royalties; J&J’s medtech portfolio lead; Huawei hits Verizon in $1bn suit; plus much more

Everything we covered on IAM over the last seven days – and all you need to know from the global IP market to set yourself up for the start of another busy week

MONDAY 3rd February

IP leaders from Samsung, Daimler, Tivo and others explain how they get the most out of their Indian R&D functions. Read more here

The former chief IP officer of Ericsson argues that a one-size-fits-all approach to licensing the new generation of wireless technology does not make economic or commercial sense. Read more here

Months after taking control of a portfolio of IBM patents, an NPE has filed its first suit in the Western District of Texas accusing a Chinese drone maker of infringing three of them. Read more here

TUESDAY 4th February

Indonesia has rolled out a new framework for compulsory licensing, including special provisions related to semiconductors. Read more here

Judgments from the CJEU rejecting a presumption of confidentiality for clinical study reports submitted for marketing authorisation have significant implications for pharma data strategies. Read more here

Caltech’s massive patent award against Apple and Broadcom ranks among top 10 largest victories - but the iPhone maker has a habit of overturning nine-figure judgments. Read more here

WEDNESDAY 5th February

China Coronavirus treatment patent application unlikely to succeed in light of Gilead's prior art, practitioners say. Company is cooperating on clinical trials with Chinese partners. Read more here

There are four primary reasons why applicants – particularly those without extensive R&D backing – struggle to get USPTO approval for quantum computing patents. Read more here

Standards essential patent owners now have a clearer and potentially more favourable option for asserting their rights in the US. Read more here

THURSDAY 6th February

Huawei makes good on $1 billion Verizon patent threat by launching US suits that accuse the wireless carrier of infringing 12 of its rights. Read more here

The UPC, the rise of AI, international patent litigation and patent dealmaking were among the hot topics discussed at this year’s IAM Biotech and Pharma IP conference in London. Read more here

USPTO Director makes clear US concerns about a Chinese head of WIPO, saying that the next leader of the organisation must come from a country that “respects intellectual property rights”. Read more here

FRIDAY 7th February

SMIC, a publicly-traded foundry from China, is the latest chip foundry to find itself in the crosshairs of US NPE Innovative Foundry Technologies. Read more here

Johnson & Johnson has surpassed other healthcare powerhouses in the medtech patent stakes and kept Apple and Alphabet at bay, but a robust portfolio does not guarantee smooth sailing. Read more here

Qualcomm continues to see big royalties uplift after Apple settlement, while Nokia’s licensing income suggests it is still waiting for a significant monetary boost from 5G. Read more here

SATURDAY 8th February

A lack of foresight and a complete absence of joined up thinking in both the US and Europe have gifted China 5G leadership. Read more here

Unlock unlimited access to all IAM content